for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Moderna Inc

MRNA.O

Latest Trade

18.40USD

Change

0.41(+2.28%)

Volume

1,093,298

Today's Range

17.71

 - 

18.50

52 Week Range

11.54

 - 

29.79

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
17.99
Open
18.00
Volume
1,093,298
3M AVG Volume
52.44
Today's High
18.50
Today's Low
17.71
52 Week High
29.79
52 Week Low
11.54
Shares Out (MIL)
333.25
Market Cap (MIL)
5,995.17
Forward P/E
-11.87
Dividend (Yield %)
--

Latest Developments

More

Moderna Receives FDA Fast Track Designation For Propionic Acidemia Program

Moderna Announces Open IND For Propionic Acidemia Program (Mrna-3927)

Harvard University Establishes mRna Immunotherapy Research Collaboration With Moderna

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Moderna Inc

Moderna, Inc. is engaged in transformative medicines based on messenger ribonucleic acid (mRNA). It has created a platform to improve the underlying pharmaceutical properties of our mRNA medicines. Its platform consists of three areas: mRNA technologies, delivery technologies, and manufacturing processes. It is pursuing mRNA science to minimize the undesirable activation of the immune system by mRNA and to maximize the potency of mRNA once in the target cells. It has advanced in parallel a diverse development pipeline of 21 programs, of which 10 have entered clinical studies and another three have open INDs. Its therapeutics and vaccine development programs span infectious diseases, oncology, cardiovascular diseases, and rare genetic diseases. It has created six modalities prophylactic vaccines, cancer vaccines, intratumoral immmuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics and systemic intracellular therapeutics.

Industry

Biotechnology & Drugs

Contact Info

200 Technology Sq

+1.617.7146500

https://www.modernatx.com/

Executive Leadership

Noubar B. Afeyan

Non-Executive Independent Chairman of the Board, Co-Founder

Stephen Hoge

President

Stephane Bancel

Chief Executive Officer, Director

Lorence Kim

Chief Financial Officer

Juan Andres

Chief Technical Operations and Quality Officer

Key Stats

1.80 mean rating - 10 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2018

0.1K

2019(E)

0.1K
EPS (USD)

2018

-4.950

2019(E)

-1.515
Price To Earnings (TTM)
--
Price To Sales (TTM)
73.49
Price To Book (MRQ)
4.78
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
2.70
LT Debt To Equity (MRQ)
2.70
Return on Investment (TTM)
-38.77
Return on Equity (TTM)
-34.57

Latest News

Latest News

European biotech firm BioNTech reverses course in early trading

Shares of BioNTech SE <BNTX.O> tumbled nearly 12% in afternoon trade, erasing all its gains from earlier on Thursday, another sign of weakness in the IPO market after the collapse of WeWork's market debut.

European biotech firm BioNtech jumps 10% in U.S. market debut

Oct 10 - Shares of BioNTech SE jumped on their market debut on Thursday, after the German biotech firm downsized its initial public offering (IPO) and priced its stock below an earlier expected range.

European biotech firm BioNtech plans to raise nearly $304 million in U.S. IPO

BioNtech SE, Europe's largest unlisted biotech firm by staff numbers, said on Tuesday that it planned to raise up to $303.6 million (243.2 million pounds) in an initial public offering in the United States.

BioNTech hires banks for IPO worth up to $800 million: sources

BioNTech, Europe's largest unlisted biotech firm by staff numbers, has hired banks to prepare for an initial public offering (IPO) worth as much as $800 million as early as this year, people familiar with the plan told Reuters.

Biotech firm Gossamer files for IPO

U.S. Biotech company Gossamer Bio Inc on Friday filed with regulators to raise up to $264.5 million and list its shares on the Nasdaq under the symbol "GOSS".

Alector, Gossamer chase Moderna with biotechnology IPOs: sources

U.S. biotechnology startups Alector LLC and Gossamer Bio are preparing for initial public offerings (IPOs) in early 2019, people familiar with the matter said on Friday, after Moderna Inc <MRNA.O> earlier this month became the sector's biggest company to ever launch an IPO.

IPO activity next year could dampen if markets do not rebound: report

The excitement of proposed initial public offerings by ride-hailing rivals Uber and Lyft next year may not be enough to encourage other firms to follow suit, as they fear that slowing global growth and rocky stock markets dragging into next year could threaten market debut...

China's Tencent Music debut strikes a chord with investors

Shares of China-based music streaming company Tencent Music Entertainment Group <TME.N> rose in their U.S. debut on Wednesday, as investors shrugged off volatile markets to grab a piece of the fast-growing music streaming industry.

Breakingviews - Uber and Lyft race to get through open IPO window

Uber and Lyft are jockeying for pole position to get through the window for initial public offerings while it’s open. The ride-hailing companies have made confidential filings for deals that could value the former at up to $120 billion and the later at more than $15 billion...

Wall Street tumbles, indexes post biggest weekly losses since March

Wall Street's main indexes fell more than 2 percent on Friday in a broad sell-off led by declines in big Internet and technology shares, and posted their largest weekly percentage drops since March as concerns over U.S.-China trade tensions and interest rates convulsed Wall...

Exclusive: Chat-service firm Slack taps Goldman Sachs to lead IPO - sources

Slack Technologies Inc, a provider of chat and direct messaging services for businesses, has hired investment bank Goldman Sachs Group Inc <GS.N> to lead its initial public offering (IPO) next year as an underwriter, people familiar with the matter said.

US STOCKS-Wall Street drops 2 pct as trade worries flare

* U.S. ready with tariffs if China talks unsuccessful-Navarro

Moderna, largest biotech to go public, fails to impress in market debut

Moderna Inc's <MRNA.O> shares fell as much as 6 percent in an upsized market debut on Friday, taking a hit from a broader selloff in U.S. markets spurred by investor concerns over an economic slowdown amid renewed trade tensions.

Moderna, largest biotech to go public, fails to impress in market debut

Moderna Inc's shares fell as much as 6 percent in an upsized market debut on Friday, taking a hit from a broader selloff in the U.S. markets spurred by investors fretting over an economic slowdown.

PRESS DIGEST -Wall Street Journal - Dec 7

The following are the top stories in the Wall Street Journal. Reuters has not verified these stories and does not vouch for their accuracy.

Exclusive: Moderna to raise $604 million in upsized IPO, braving market jitters

Moderna Inc <MRNA.O> will sell around $604.3 million (473.1 million pounds) in shares in its initial public offering (IPO), the biotech company said on Thursday, braving stock market jitters to sell more stock than originally planned.

Ride-hail firm Lyft races to leave Uber behind in IPO chase

Ride-hailing company Lyft Inc beat bigger rival Uber Technologies Inc [UBER.UL] in filing for an initial public offering (IPO) on Thursday, defying the recent market jitters and taking the lead on a string of billion-dollar-plus tech companies expected to join Wall Street...

Moderna braves market jitters with upsized IPO -source

Moderna Inc <MRNA.O> aimed to sell around $618 million in shares in its initial public offering on Thursday, a person familiar with the matter said, braving stock market jitters to sell more stock than originally planned.

Moderna braves market jitters with upsized IPO - source

Moderna Inc <MRNA.O> aimed to sell around $618 million in shares in its initial public offering on Thursday, a person familiar with the matter said, braving stock market jitters to sell more stock than originally planned.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up